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Introduction: Salivary gland–type cancers are rare lung neoplasms 
involving mucoepidermoid carcinoma (MEC), adenoid cystic carci-
noma (ACC), and epithelial–myoepithelial carcinoma (EMC). Their 
behavior and prognostic features are not clearly defined because of 
their low incidence. We retrospectively analyzed the clinicopatho-
logic profiles of these tumors in a large series.
Methods: Eighty-eight patients confirmed as having primary sali-
vary gland–type lung cancer between May 2001 and January 2013 
were included from the archives of two thoracic oncology center 
institutions in China and retrospectively evaluated.
Results: Of the total 88 patients, 69 were MEC, 12 ACC, and seven 
EMC. Overall survival (OS) at 3, 5, and 10 years was 91.3%, 86%, 
and 80.6% in all cases, respectively, and disease-free survival (DFS) 
was 90.1%, 78.6%, and 55%, respectively. No significant difference 
was found among MEC, ACC, and EMC groups regarding OS (p = 
0.518) and DFS (p = 0.082). Tumor-node-metastasis stage, lymph 
node involvement, intrathoracic invasion, and margin status were 
found to be related with OS (p = 0.000, 0.029, 0.000, 0.004) and 
DFS (p = 0.018, 0.042, 0.002, 0.002). Intrathoracic invasion was an 
independent predictor for OS (hazard ratio [HR], 1.129; p = 0.039) 
and DFS (HR, 1.071; p = 0.011). For patients with MEC, pathologi-
cal grade also was an independent predictor of OS (HR, 0.045; p = 
0.006) and DFS (HR, 0.067; p = 0.001).
Conclusions: Salivary gland–type lung cancers are a group of low-
aggressive entities with higher tendency to recurrence/metastasis. 
Intensive clinical, radiological, and pathological examinations are 
essential to estimation of the risk stratification and management.
Key Words: Salivary gland–type lung cancer, Mucoepidermoid carci-
noma, Adenoid cystic carcinoma, Epithelial–myoepithelial carcinoma.
(J Thorac Oncol. 2013;8: 1578–1584)
Primary salivary gland–type lung cancer is rare and rep-resents less than 1% of all lung tumors.1,2 This group of 
tumors derives from small salivary glands in the respiratory 
system3 and mainly include two common histological sub-
types of mucoepidermoid carcinoma (MEC) and adenoid 
cystic carcinoma (ACC) and a less common subtype of epithe-
lial–myoepithelial carcinoma (EMC).4–6 Previously, salivary 
gland–type lung cancer was mostly reported in small series5,7,8 
or described in case reports9–11 because of its low incidence. 
Thus, relatively little is known about their precise clinical, 
radiological, and pathological features. Consequently, no con-
sensus on optimal therapeutic strategy is available. The present 
study aimed to review salivary gland–type lung cancer, with 
emphasis on clinical behavior, pathologic features, treatment, 
and prognostic factors in a large series of Chinese patients.
MATERIALS AND METHODS
This retrospective study was approved by the 
Institutional Review Board. Between May 2001 and January 
2013, patients with primary salivary gland–type cancer were 
identified pathologically from two thoracic oncology centers 
(Zhongshan Hospital and Chest Hospital, Shanghai, China). 
Diagnosis of MEC, ACC, and EMC was made according 
to the World Health Organization classification of thoracic 
tumors.12 MEC was graded in line with the algorithm pro-
posed by Auclair et al.13 The grading of ACC and EMC was 
not performed. Staging was performed in compliance with the 
tumor-node-metastasis (TNM) staging system of the American 
Joint Committee on Cancer (7th edition). Follow-ups were 
conducted via medical records plus telephone interview.
Survival was calculated using the Kaplan–Meier 
method, and the survival curves were compared by the log-
rank test. Cox’s proportional hazards regression model 
was used for univariate and multivariate survival analysis. 
Categorical variables were presented as counts and percent-
ages, and comparisons were conducted using Fisher’s exact 
tests. Continuous variables were presented as median and 
range, and comparisons were conducted using one-way analy-
sis of variance. All analyses were performed using IBM SPSS 
Statistics 20.0 (IBM Corporation, New York, NY).
RESULTS
Clinical Characteristics
In total, 69 MEC, 12 ACC, and seven EMC patients were 
identified. Patient characteristics are summarized in Table 1. 
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TABLE 1.  Characteristics of Patients with Salivary Gland–Type Lung Cancer
Variables
No. of Patients (%)
pTotal (N = 88) MEC (n = 69) ACC (n = 12) EMC (n = 7)
Median age [range] 48 [7–75] 47.5 [7–73] 47.5 [26–64] 63 [36–75] 0.134
Sex
  Male 47 (53.4) 38 (55.1) 6 (50.0) 3 (42.9) 0.799
  Female 41 (46.6) 31 (44.9) 6 (50.0) 4 (57.1)
Smoking 14 (15.9) 11 (15.9) 2 (16.7) 1 (14.3) 1.000
Presenting symptoms
  Cough 43 (48.9) 34 (49.3) 6 (50) 3 (42.9) 1.000
  Hemoptysis 18 (20.5) 16 (23.2) 1 (8.3) 1 (14.3) 0.631
  Fever 14 (15.9) 11 (15.9) 1 (8.3) 2 (28.6) 0.437
  Dyspnea 8 (9.1) 5 (7.2) 2 (16.7) 1 (14.3) 0.271
  Chest pain 5 (5.7) 5 (7.2) 0 (0) 0 (0) 1.000
  Shortness of breath 4 (4.5) 3 (4.3) 1 (8.3) 0 (0) 0.629
  Wheezing 1 (1.1) 1 (1.4) 0 (0) 0 (0) 1.000
  Limbs numbness 1 (1.1) 1 (1.4) 0 (0) 0 (0) 1.000
  Back pain 1 (1.1) 1 (1.4) 0 (0) 0 (0) 1.000
  Asymptomatic 19 (21.6) 15 (21.7) 3 (25) 1 (14.3) 0.901
Location
  Trachea 5 (5.7) 3 (4.3) 2 (16.7) 0 (0) 0.182
  Right main bronchus 4 (4.5) 2 (2.9) 0 (0) 2 (28.6) 0.051
  Left main bronchus 5 (5.7) 3 (4.3) 2 (16.7) 0 (0) 0.182
  Right upper lobe 12 (13.6) 10 (14.5) 1 (8.3) 1 (14.3) 1.000
  Right middle lobe 8 (9.1) 8 (11.6) 0 (0) 0 (0) 0.642
  Right lower lobe 18 (20.5) 14 (20.3) 2 (16.7) 2 (28.6) 0.793
  Left upper lobe 23 (26.1) 19 (27.5) 3 (25.0) 1 (14.3) 0.908
  Left lower lobe 13 (14.8) 10 (14.5) 2 (16.7) 1 (14.3) 1.000
Tumor size [range] 2.5 [0.5–12] 2.65 [0.5–10] 3.0 [1.5–12] 2.5 [1.3–4.0] 0.476
 TNM stage
  I 61 (69.3) 48 (69.6) 6 (50) 7 (100) 0.073
  II 16 (18.2) 12 (17.4) 4 (33.3) 0 (0) 0.263
  III 9 (10.2) 8 (11.6) 1 (8.3) 0 (0) 1.000
  IV 2 (2.3) 1 (1.4) 1 (8.3) 0 (0) 0.387
Intrathoracic invasion
  No 67 (76.1) 53 (76.8) 7 (58.3) 7 (100) 0.151
  Yes 21 (23.9) 16 (23.1) 5 (41.6) 0 (0)
LN involvement
  No 73 (83) 57 (82.6) 9 (75) 7 (100) 0.451
  Yes 15 (11.4) 12 (17.4) 3 (25) 0 (0)
Treatment
  Surgical
   Tracheal resection 5 (5.7) 3 (4.3) 2 (16.7) 0 (0) 0.182
   Lobectomy 49 (55.7) 38 (55.1) 6 (50) 5 (71.4) 0.692
   Sleeve lobectomy 16 (18.2) 13 (18.8) 2 (16.7) 1 (14.3) 1.000
   Wedge lobectomy 2 (2.3) 2 (2.9) 0 (0) 0 (0) 1.000
   VATS 9 (10.2) 8 (11.6) 1 (8.3) 0 (0) 1.000
   Pneumonectomy 3 (3.4) 2 (2.9) 0 (0) 1 (14.3) 0.266
  Chemotherapy 4 (4.5) 3 (4.3) 1 (8.3) 0 (0) 0.629
Resection margin
  Negative 77 (87.5) 62 (89.9) 8 (66.7) 7 (100) 0.067
  Positive 7 (8.0) 4 (5.8) 3 (25) 0 (0)
(Continued)
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Postoperative treatment
  Radiotherapy 10 (11.4) 6 (7.2) 3 (25) 1 (14.3) 0.144
  Chemotherapy 7 (8) 7 (10.1) 0 (0) 0 (0) 0.773
Recurrence/metastasis
  No 73 (83.0) 60 (87.0) 7 (58.3) 6 (85.7) 0.057
  Yes 15 (17.0) 9 (13.0) 5 (41.7) 1 (14.3)
MEC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; EMC, epithelial–myoepithelial carcinoma; TNM, tumor-node-metastasis; LN, lymph node; VATS, video-
assisted thoracic surgery.
TABLE 1.  (Continued)
Variables
No. of Patients (%)
pTotal (N = 88) MEC (n = 69) ACC (n = 12) EMC (n = 7)
FIGURE 1.  Radiological findings of patients with salivary gland–type lung cancer. A, Low-grade mucoepidermoid carcinoma in 
a 36-year-old man. CT shows an endobronchial lesion with stenosis of right main bronchus and formation of nodule (arrow).  
B, High-grade mucoepidermoid carcinoma in a 70-year-old man. Enhanced CT shows a lobulated, heterogenous mass in the 
right lower lobe (arrow). C–E, Adenoid cystic carcinoma in a 62-year-old man. PET (C), CT (D), and PET/CT (E) images show 
an oval nodule with slight but obvious increased (18)F-fluoro-2-deoxy-D-glucose (18 F-FDG) uptake in the right lower lobe 
(arrows). Maximum standardized uptake value was 1.3. CT, computed tomography; PET, positron emission tomography. 
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None of the clinical parameters included in Table 1 were 
found to significantly correlate with histological subtypes.
Radiological Appearance
The findings were obtained of computed tomog-
raphy (CT) or positron emission tomography/CT before 
treatment in 30 patients with MEC and eight with ACC. CT 
images showed lesions in the central (n = 26) or periph-
eral (n = 12) lung. The contour of the tumors were round 
to oval (n = 31) or lobulated (n = 7). In 20 central MEC 
tumors, three revealed lobulated masses and the remain-
ing showed oval nodules projecting into the bronchus 
FIGURE 2.  Morphology of MEC, ACC, and EMC, H&E &400. A, Low-grade MEC was characterized by frequent cysts com-
posed of bland mucous neoplastic cells. B, Intermediate-grade MEC was characterized by less frequent cysts composed of 
neoplastic cells with slight atypia, and more epithelioid cells. C, High-grade MEC was characterized by scanty cysts and pleo-
morphic neoplastic cells. D, Oncocytic variant of MEC was composed of neoplastic cells with clear to eosinophilic cytoplasm. E, 
Cribriform ACC demonstrated nests of cells with cylindromatous microcystic spaces containing basophilic mucoid material. F, 
EMC was characterized by binary cell components; the inner ductal cells were cuboidal and basophilic, and the outer myoepi-
thelial cells were clear-looking. MEC, mucoepiderrmoid carcinoma; ACC, adenoid cystic carcinoma; EMC, epithelial–myoepithe-
lial carcinoma; H&E, hematoxylin and eosin.
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(Fig. 1A). Ten peripheral MEC tumors exhibited oval 
nodules (n = 4) or masses (n = 6) with rough margin 
( Fig. 1B). CT images exposed peripheral lung lesions in six 
and central lung lesions in two patients with ACC; five of 
these showed oval nodules and the other three cases were 
lobulated masses. One ACC case that underwent positron 
emission tomography/CT showed slight but obviously 
increased (18)F-fluoro-2-deoxy-D-glucose (18 F-FDG) 
uptake within the tumor (Fig. 1C–E). In general, the radio-
logical profile of ACC was similar to that of MEC.
Histopathological Features
Histopathological examination of MEC showed that 45 
tumors were low grade, 11 were intermediate grade, and 13 were 
high grade. Briefly, the low-grade MEC demonstrated frequent 
macrocysts and microcysts, mucous cells, bland cytologic fea-
tures, and few mitoses (Fig. 2A). High-grade MEC was char-
acterized by few cysts, few mucous cells, frequent mitoses, and 
cellular pleomorphism (Fig. 2C). The intermediate-grade MEC 
represented an intermediate histology in the spectrum from low 
grade to high grade (Fig. 2B). One case of MEC variant with 
oncocytic cells was identified, in which cells with eosinophilic 
cytoplasm predominated (Fig. 2D). All ACC tumors were in crib-
riform pattern, demonstrating nests of cells with cylindromatous 
microcystic spaces that contained hyaline or basophilic mucoid 
material (Fig. 2E). EMC cases imparted a bilayered duct-like 
histology. The inner layer was lined by cuboidal cells, with finely 
granular cytoplasm; the outer layer was composed of myoepithe-
lial cells with clear cytoplasm (Fig. 2F).
Clinical Follow-Up
The median follow-up duration was 49 months (range, 
3–134 months), during which the tumor recurrence/metasta-
sis was identified in 15 patients (Table 2), of whom four had 
positive resection margin at the time of primary surgery. No 
significant difference was found among the three groups on 
recurrence/metastasis (Table 1; p = 0.057).
Overall survival (OS) at 3, 5, and 10 years was 91.3%, 
86%, and 80.6%, respectively, and disease-free survival 
(DFS) was 90.1%, 78.6%, and 55%, respectively. There 
was no significant difference among the MEC, ACC, and 
EMC groups regarding OS (Fig. 3A; p = 0.518) and DFS 
(Fig. 3B; p = 0.082). OS and DFS in surgical patients with dif-
ferent histological subtypes are shown in Table 3. TNM stage, 
lymph node involvement, intrathoracic invasion, and margin 
status were found to be related with OS and DFS (Table 4). 
Moreover, there was a higher risk of OS (p < 0.001; Fig. 
3C) and DFS (p < 0.001; Fig. 3D) in high-grade MEC cases 
than low to intermediate ones. Multivariate analysis showed 
thoracic invasion was a significant determinant of OS (haz-
ard ratio [HR], 1.129; 95% confidence interval [CI], 1.006–
1.266; p = 0.039) and DFS (HR, 1.071; 95% CI, 1.016–1.128; 
p = 0.011) for all cases, and pathological grade was a sig-
nificant predictor of OS (HR, 0.045; 95% CI, 0.005–0.410; 
p = 0.006) as well as DFS (HR, 0.067; 95% CI, 0.013–0.337; 
p = 0.001) for patients with MEC.
DISCUSSION
In the present study of a cohort of salivary gland–type 
lung cancer patients with a long follow-up, we found that 
MEC was the most common histological subtype of sali-
vary gland–type lung cancers, followed by ACC, and our 
findings are in general consistent with findings of the previ-
ous series.4,6,10 Nevertheless, patient demographic informa-
tion, clinical presentation, and radiological appearance are 
diverse and lack characteristic features. Thus, pathological 
examination tends to be the exclusive means to distinguish 
salivary gland–type lung cancer from other pulmonary 
lesions. However, salivary gland–type lung tumors are eas-
ily diagnosed as common lung cancers in pathology, such as 
adenosquamous carcinoma because of lack of specific bio-
logical markers to facilitate diagnosis as well as differential 
diagnosis. For samples obtained from endoscopy or pneu-
mocentesis, diagnosis may be more difficult based on lim-
ited biopsied tissue. It can be seen that exploring biological 
markers specific for MEC, ACC, and EMC is of importance.
TNM stage, intrathoracic invasion, lymph node involve-
ment, and margin status were associated with OS and DFS of 
salivary gland–type lung cancer patients. Tumor grade may 
predict the OS and DFS of MEC patients, yet considerations 
of tumor grade with intrathoracic invasion are of predictive 
value by multivariate analysis. Even if some parameters are 
not independent prognostic factors, we propose that all the 
significant factors described above are worthy of consider-
ation for physicians deciding rational therapeutic strategies. 
Interestingly, no significant difference was seen on the sur-
vival among MEC, ACC, and EMC groups, and this result 
differed from observations made by Hickman et al.14 regard-
ing salivary carcinomas of head and neck. Besides anatomical 
difference of tumor sites and variation of series, we attributed 
this difference to the predominance of surgical management 
in ACC patients in the study by Hickman et al.
TABLE 2.  Brief Information of Tumor Recurrence/Metastasis
No.
Histological 
Subtype Grade
Recurrence/Metastasis 
(site) Survival
1 MEC Low Ipsilateral lung Alive
2 MEC Low Contralateral lung Died
3 MEC High Ipsilateral lung Alive
4 MEC High Ipsilateral lung Alive
5 MEC High Contralateral lung Died
6 MEC High Mediastina Died
7 MEC High Liver Died
8 MEC High Adrenal gland Died
9 MEC High Bone Died
10 ACC — Ipsilateral lung Alive
11 ACC — Contralateral lung Alive
12 ACC — Diaphragm Alive
13 ACC — Contralateral lung Died
14 ACC — Brain, bone Died
15 EMC — Bone Alive
MEC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; EMC, 
epithelial–myoepithelial carcinoma.
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As far as treatment options for salivary gland–type lung 
cancer are concerned, surgical intervention seems optimal, 
given that limited disease is predominant, and the surgical plan 
relies on the clinical status of the patient. Complete surgical 
resection is associated with a favorable long-term outcome, 
as demonstrated by the present study that positive resection 
margin had imposed a negative effect on OS and DFS. This 
finding suggests that salivary gland–type cancer of the lung 
TABLE 3.  Histological Subtypes of Survival in Surgical Patients
Subtype
Overall Survival (%)
pa
Disease-Free Survival (%)
pb3-Year 5-Year 10-Year 3-Year 5-Year 10-Year
MEC (n = 66) 93.1 89.5 82.6 0.781 94.7 87.3 53.7 0.082
ACC (n = 11) 88.9 88.9 — 69.3 46.2 —
EMC (n = 7) 100 100 — 85.7 85.7 —
ap value is comparision among the MEC, ACC, and EMC groups for overall survival.
bp value is comparision among the MEC, ACC, and EMC groups for disease-free survival.
MEC, mucoepidermoid carcinoma; ACC, adenoid cystic carcinoma; EMC, epithelial–myoepithelial carcinoma.
FIGURE 3.  Kaplan–Meier curves comparing OS and DFS. A, OS and (B) DFS of patients with different histological subtypes;  
(C) OS and (D) DFS of patients with different pathological grades. OS, overall survival; DFS, disease-free survival.
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should be removed as completely as possible. According to 
the current analysis, lymphadenectomy and postoperative 
radiotherapy did not confer survival benefit on nonselective 
patients. So, it does not seem necessary to perform lymph-
adenectomy and postoperative radiotherapy on every patient 
with MEC, ACC, or EMC. Only patients with evidence of 
lymph node involvement may benefit from lymphadenectomy. 
Additionally, adjuvant radiotherapy could be performed if the 
resection margins are proved to be positive. More prospective 
studies are needed to reveal the optimal therapy. Currently, 
patients with salivary gland–type lung cancer may be safely 
managed through multidisciplinary approaches.
As previously reported,15 the clinical behavior of MEC 
of the head and neck could be predicted by pathological grade. 
Similar findings have been shown for MEC of the lung in the 
present study. The present study showed that high-grade MEC 
tumors had more aggressive clinical behavior and higher inci-
dence of recurrence/metastasis with poor survival. However, 
to date, grading for ACC and EMC tumor is still not well 
defined. Thus, more studies remain necessary to propose a 
reproducible and precise grading system for ACC and EMC.
In conclusion, salivary gland–type lung cancer is a 
group of complex neoplasms with a wide spectrum of clini-
cal presentation and nonspecific radiographic manifestations. 
No significant prognostic difference was found among the 
MEC, ACC, and EMC groups. Pathological grade, TNM 
stage, and complete tumor resection are important prognostic 
factors. Further prospective studies are needed to confirm our 
findings.
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